Yourway, courier and clinical packager offering integrated clinical trial supply chain solutions, announced its establishment of a new location within the European Union providing storage and distribution services, including secondary packaging capabilities, located 40 minutes from the Vienna, Austria airport in Bratislava, Slovakia. This move was designed to ensure uninterrupted support for clients’ trials in both the UK and mainland Europe if the United Kingdom leaves the EU on the current deadline of October 31, especially in the event of a no-deal Brexit.
“The new location in Europe mitigates the uncertainty of Brexit for our clients, in order to service their clinical trial needs. It includes Qualified Person (QP) release services within Europe prior to release for use in a Clinical Trial, as required by Clinical Trial Directive 2001/20/EC and Annex 13 to the European GMP Guide.” said Yourway President and Founder, Gulam Jaffer.
“Through our Project Managers and QP release personnel, and use of our global network of GMP depots, we can assure safe and timely delivery of clinical trial materials to patients,” he added.
Yourway provides a full range of temperature-controlled solutions designed to protect clinical trial shipments from the time an order is received through to delivery on time for patient dosing protocols. It is also offering an integrated supply chain with no differences in quality to traditional multi-provider models in this market.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.